Protirelin treatment in critically ill severe head-injured patients: A double-blind, placebo-controlled, prospective study

N. Latronico, M. Bochicchio, P. Montaguti, S. Cappa, G. Perone, A. Tansini, A. Tonnelli, A. Candiani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In addition to its neuroendocrine function, thyrotropin releasing hormone (TRH), may act as a neurotransmitter and neuromodulator within the CNS. Data exist to suggest a key role for this drug in the treatment of disturbances of consciousness. In this double-blind, placebo-controlled prospective study, 91 patients with severe head injury (GCS score ≤ 8 for at least six hours) were randomly assigned to receive either placebo or protirelin TRH-T (2 mg 12 hourly) for two weeks. A standard, brain-oriented therapy was otherwise maintained for both groups. The patients were comparable in terms of age, neurological and injury severity scores on admission. Most patients had severe extracranial injuries and/or systemic insults, such as hypoxia and hypotension, in addition to brain trauma. As expected, the mortality rate was high (40.0% protirelin, 58.7% placebo). However, patients treated with protirelin had a shorter duration of impaired consciousness and, therefore, a shorter ICU stay. Furthermore, they showed better functional recovery six months after trauma; 23 of them (51.1%) made a good recovery or had only moderate disabilities, as compared with 13 (28.3%) in the placebo group. Extensive neuropsychological evaluation of this sub-group of patients showed better performance in the protirelin group. However, the small sample size precluded definite conclusions. In conclusion, the present data provide preliminary evidence of the safety of protirelin in the treatment of severe brain trauma.

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalClinical Intensive Care
Volume4
Issue number4
Publication statusPublished - 1993

Fingerprint

Thyrotropin-Releasing Hormone
Critical Illness
Head
Placebos
Prospective Studies
Consciousness
Therapeutics
Neurotransmitter Agents
Injury Severity Score
Wounds and Injuries
Craniocerebral Trauma
Sample Size
Hypotension
Safety
Mortality
Brain
Pharmaceutical Preparations

Keywords

  • Head trauma
  • Neuropeptides
  • Protirelin
  • TRH

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Latronico, N., Bochicchio, M., Montaguti, P., Cappa, S., Perone, G., Tansini, A., ... Candiani, A. (1993). Protirelin treatment in critically ill severe head-injured patients: A double-blind, placebo-controlled, prospective study. Clinical Intensive Care, 4(4), 166-173.

Protirelin treatment in critically ill severe head-injured patients : A double-blind, placebo-controlled, prospective study. / Latronico, N.; Bochicchio, M.; Montaguti, P.; Cappa, S.; Perone, G.; Tansini, A.; Tonnelli, A.; Candiani, A.

In: Clinical Intensive Care, Vol. 4, No. 4, 1993, p. 166-173.

Research output: Contribution to journalArticle

Latronico, N, Bochicchio, M, Montaguti, P, Cappa, S, Perone, G, Tansini, A, Tonnelli, A & Candiani, A 1993, 'Protirelin treatment in critically ill severe head-injured patients: A double-blind, placebo-controlled, prospective study', Clinical Intensive Care, vol. 4, no. 4, pp. 166-173.
Latronico N, Bochicchio M, Montaguti P, Cappa S, Perone G, Tansini A et al. Protirelin treatment in critically ill severe head-injured patients: A double-blind, placebo-controlled, prospective study. Clinical Intensive Care. 1993;4(4):166-173.
Latronico, N. ; Bochicchio, M. ; Montaguti, P. ; Cappa, S. ; Perone, G. ; Tansini, A. ; Tonnelli, A. ; Candiani, A. / Protirelin treatment in critically ill severe head-injured patients : A double-blind, placebo-controlled, prospective study. In: Clinical Intensive Care. 1993 ; Vol. 4, No. 4. pp. 166-173.
@article{5762b50a8d7a4bf79342167c0bca5d02,
title = "Protirelin treatment in critically ill severe head-injured patients: A double-blind, placebo-controlled, prospective study",
abstract = "In addition to its neuroendocrine function, thyrotropin releasing hormone (TRH), may act as a neurotransmitter and neuromodulator within the CNS. Data exist to suggest a key role for this drug in the treatment of disturbances of consciousness. In this double-blind, placebo-controlled prospective study, 91 patients with severe head injury (GCS score ≤ 8 for at least six hours) were randomly assigned to receive either placebo or protirelin TRH-T (2 mg 12 hourly) for two weeks. A standard, brain-oriented therapy was otherwise maintained for both groups. The patients were comparable in terms of age, neurological and injury severity scores on admission. Most patients had severe extracranial injuries and/or systemic insults, such as hypoxia and hypotension, in addition to brain trauma. As expected, the mortality rate was high (40.0{\%} protirelin, 58.7{\%} placebo). However, patients treated with protirelin had a shorter duration of impaired consciousness and, therefore, a shorter ICU stay. Furthermore, they showed better functional recovery six months after trauma; 23 of them (51.1{\%}) made a good recovery or had only moderate disabilities, as compared with 13 (28.3{\%}) in the placebo group. Extensive neuropsychological evaluation of this sub-group of patients showed better performance in the protirelin group. However, the small sample size precluded definite conclusions. In conclusion, the present data provide preliminary evidence of the safety of protirelin in the treatment of severe brain trauma.",
keywords = "Head trauma, Neuropeptides, Protirelin, TRH",
author = "N. Latronico and M. Bochicchio and P. Montaguti and S. Cappa and G. Perone and A. Tansini and A. Tonnelli and A. Candiani",
year = "1993",
language = "English",
volume = "4",
pages = "166--173",
journal = "Clinical Intensive Care",
issn = "0956-3075",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Protirelin treatment in critically ill severe head-injured patients

T2 - A double-blind, placebo-controlled, prospective study

AU - Latronico, N.

AU - Bochicchio, M.

AU - Montaguti, P.

AU - Cappa, S.

AU - Perone, G.

AU - Tansini, A.

AU - Tonnelli, A.

AU - Candiani, A.

PY - 1993

Y1 - 1993

N2 - In addition to its neuroendocrine function, thyrotropin releasing hormone (TRH), may act as a neurotransmitter and neuromodulator within the CNS. Data exist to suggest a key role for this drug in the treatment of disturbances of consciousness. In this double-blind, placebo-controlled prospective study, 91 patients with severe head injury (GCS score ≤ 8 for at least six hours) were randomly assigned to receive either placebo or protirelin TRH-T (2 mg 12 hourly) for two weeks. A standard, brain-oriented therapy was otherwise maintained for both groups. The patients were comparable in terms of age, neurological and injury severity scores on admission. Most patients had severe extracranial injuries and/or systemic insults, such as hypoxia and hypotension, in addition to brain trauma. As expected, the mortality rate was high (40.0% protirelin, 58.7% placebo). However, patients treated with protirelin had a shorter duration of impaired consciousness and, therefore, a shorter ICU stay. Furthermore, they showed better functional recovery six months after trauma; 23 of them (51.1%) made a good recovery or had only moderate disabilities, as compared with 13 (28.3%) in the placebo group. Extensive neuropsychological evaluation of this sub-group of patients showed better performance in the protirelin group. However, the small sample size precluded definite conclusions. In conclusion, the present data provide preliminary evidence of the safety of protirelin in the treatment of severe brain trauma.

AB - In addition to its neuroendocrine function, thyrotropin releasing hormone (TRH), may act as a neurotransmitter and neuromodulator within the CNS. Data exist to suggest a key role for this drug in the treatment of disturbances of consciousness. In this double-blind, placebo-controlled prospective study, 91 patients with severe head injury (GCS score ≤ 8 for at least six hours) were randomly assigned to receive either placebo or protirelin TRH-T (2 mg 12 hourly) for two weeks. A standard, brain-oriented therapy was otherwise maintained for both groups. The patients were comparable in terms of age, neurological and injury severity scores on admission. Most patients had severe extracranial injuries and/or systemic insults, such as hypoxia and hypotension, in addition to brain trauma. As expected, the mortality rate was high (40.0% protirelin, 58.7% placebo). However, patients treated with protirelin had a shorter duration of impaired consciousness and, therefore, a shorter ICU stay. Furthermore, they showed better functional recovery six months after trauma; 23 of them (51.1%) made a good recovery or had only moderate disabilities, as compared with 13 (28.3%) in the placebo group. Extensive neuropsychological evaluation of this sub-group of patients showed better performance in the protirelin group. However, the small sample size precluded definite conclusions. In conclusion, the present data provide preliminary evidence of the safety of protirelin in the treatment of severe brain trauma.

KW - Head trauma

KW - Neuropeptides

KW - Protirelin

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=0027504281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027504281&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027504281

VL - 4

SP - 166

EP - 173

JO - Clinical Intensive Care

JF - Clinical Intensive Care

SN - 0956-3075

IS - 4

ER -